Cholane-PEG Nanocarriers for Tumor Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanocarriers for cancer drug delivery, such as Abraxane and Doxil, face challenges due to their large size, which limits tumor penetration and leads to trapping in the liver and reticuloendothelial system, and most biodegradable micelles are unstable and have low drug loading capacity.
Innovation Solution
Development of smaller, stable nanocarriers with a core-shell structure formed from cholane-PEG conjugates that self-assemble in aqueous conditions, providing a hydrophobic pocket for drug loading and a hydrophilic exterior for stability and biocompatibility, allowing for tunable size and improved drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If nanocarriers are made larger to improve drug loading capacity, then drug loading capacity is improved, but tumor penetration ability deteriorates
Solution Approach 1:
The patent employs a core-shell structure where the hydrophobic core is nested within the hydrophilic shell. This nested architecture allows the nanocarrier to maintain a compact outer diameter (reducing size for better tumor penetration) while accommodating a substantial drug payload within the internal core volume (maintaining drug loading capacity).
Solution Approach 2:
The nanocarrier exhibits local quality differentiation with a hydrophobic interior region for drug encapsulation and a hydrophilic exterior region for stability in aqueous environments. This spatial differentiation of properties allows the same structure to simultaneously achieve high drug loading (through hydrophobic interactions in the core) and small effective size (through the compact shell configuration).
2Quantity of substance
If nanocarriers are made larger to improve drug loading capacity, then drug loading capacity is improved, but circulation time deteriorates due to liver and RES trapping
Solution Approach 1:
The patent optimizes the nanocarrier size parameter to fall within the 10-100 nm range, which represents a critical threshold for avoiding reticuloendothelial system recognition and clearance. This parameter optimization allows the nanocarrier to maintain sufficient drug loading capacity while achieving extended circulation half-life by evading liver and RES trapping.
Solution Approach 2:
The nanocarrier utilizes a composite architecture combining hydrophobic and hydrophilic materials in a core-shell configuration. This composite structure provides both the drug loading capacity (through hydrophobic core) and the extended circulation time (through hydrophilic shell that prevents protein adsorption and macrophage recognition).
3Ease of manufacture
If conventional micelles are used for drug delivery, then ease of manufacture is improved, but stability deteriorates
Solution Approach 1:
The amphiphilic block copolymers spontaneously self-assemble into stable micellar structures in aqueous solution without requiring external intervention or complex manufacturing processes. The hydrophobic effect drives the spontaneous organization of copolymer chains into core-shell micelles, simultaneously achieving ease of manufacture and enhanced stability through thermodynamically favorable self-assembly.
Solution Approach 2:
The use of amphiphilic block copolymers creates a composite molecular structure with distinct hydrophobic and hydrophilic segments. This composite architecture enables spontaneous micelle formation with stable core-shell morphology, combining the simplicity of self-assembly with robust structural stability that resists disassembly under physiological conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanocarriers effectively deliver paclitaxel and other hydrophobic drugs to tumor sites with enhanced clinical toxicity profile and stability, reducing side effects and improving anti-tumor efficacy while maintaining biocompatibility.
Implementation Method 1
These conjugates self-assemble in an aqueous solvent to form the nanocarrier
Implementation Method 2
a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other
Implementation Method 3
wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier
Data Source
AI summary
The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.